Cancer during pregnancy is not a frequent event. 1 Most of the cases are diagnosed during prenatal visits. It presents an ethical dilemma, because it is known that with effective chemotherapy complete remission can be obtained in up to 75% of patients with hematologic malignancies such as leukemia, 2 but it is also known that chemotherapy has potential harmful effects to the fetus. [2] [3] [4] We report two infants born to women diagnosed with a hematologic malignancy during pregnancy and treated with chemotherapeutic agents during the second and third trimesters. Both infants were born premature. One infant developed marked anemia and neutropenia requiring treatment with erythropoietin and granulocyte colony stimulating factor (G-CSF). The other infant presented with moderate leukopenia, which lasted for 2 days. Both patients survived.
CASE REPORT 1
A 21-year-old Puerto Rican female on her third pregnancy was diagnosed with acute myelogenous leukemia, M-3 (French-AmericanBritish classification) at 21 weeks' gestation in a community hospital. She was transferred to the University District Hospital in San Juan, Puerto Rico and was started on chemotherapy receiving courses of cytarabine and daunorubicin at approximately 21 and 25 weeks' gestation. She was evaluated by the Obstetrics and Gynecology Service at 25 weeks' gestation finding oligohydramnios and early intrauterine growth retardation. Because she had no response to the first two courses of chemotherapy, she was treated with cytarabine and mitoxantrone at 28 weeks' gestation. The patient developed hypertension at 27 weeks' gestation, and proteinuria 2 weeks later. Due to these complications, she was transferred to the observation area of the delivery room. At a gestation of 29 weeks and 3 days, electronic fetal monitoring showed fetal tachycardia and decelerations. A classic cesarean section was performed under general anesthesia.
She gave birth to a single preterm female baby with birth weight of 857 gm who had weight, head circumference, and length in the 10th percentile for gestational age. The newborn required resuscitation at the delivery room, had an Apgar score of 4 at 1 minute and 6 at 5 minutes and was transferred to the Neonatal Intensive Care Unit at the University Pediatric Hospital.
She was placed on mechanical ventilation and started on antibiotics. During the first day she developed hyponatremia, hypoglycemia, and seizures. These were resolved by the second postnatal day. Initial laboratories showed severe neutropenia, anemia, and thrombocytopenia becoming worst at 7 days of age ( Figure 1 ). She was given immunoglobulin on the first day of life. Bone marrow aspiration was performed on day 6 after birth, which showed complete marrow aplasia. The infant was treated with blood product transfusions, erythropoietin, and G-CSF for 7 days. Physical examination on day 1 demonstrated an abdominal mass. Sonographic examination showed bilateral hydronephrosis and dilatation of the proximal ureter of the left kidney. Due to the history of the mother having received cardiotoxic chemotherapy during her pregnancy, an echocardiogram was performed on the baby showing normal cardiac anatomy and function, with a patent foramen ovale that was expected for her age. A head sonogram showed an intracranial hemorrhage grade II that resolved at 1 month of age. The hematologic derangement was resolved after 7 days of therapy. There was no evidence of hepatic dysfunction and no infections were documented.
Current Concepts
This baby developed failure to thrive and started to gain weight progressively only after the third month of life despite an adequate caloric intake. She was discharged from the hospital at 4.5 months with a weight of 2013 gm.
CASE REPORT 2
A 30-year-old Puerto Rican female on her fifth pregnancy was diagnosed with large B cell lymphoma. She was given treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone. She received courses of chemotherapy at the 28th and 32nd weeks of gestation. She gave birth to a single preterm male baby, 1 week after her last chemotherapy course, with birth weight of 1645 gm. Weight, length, and head circumference were in the 40th percentile for gestational age. His Apgar score was 8 at 1 minute and 9 at 5 minutes. He developed clinical evidence of necrotizing enterocolitis (stage 1) and was started on antibiotic therapy. During the first week he showed leukopenia (WBC ϭ 1430), without significant neutropenia, which lasted for 2 days. Platelet counts and hemoglobin concentration were normal. He had an uneventful course and was discharged from the hospital after 10 days, without documented infection.
DISCUSSION
Chemotherapy during pregnancy has potential harmful effects to the fetus. Therapy given during the implantation phase results in a high number of abortions. During major organogenesis, the fetus is very sensitive to teratogenic effects. During the growth phase, insults related to the therapy or the disease itself, cause growth retardation. 5 Possible mechanisms for growth retardation reported by Morishita et al. 3 include: diminished oxygen transfer to the fetus caused by decreased maternal hemoglobin concentration, aggregation of leukemic cells in the utero placental circulation reducing the blood flow, and intravascular coagulation causing a vascular insult to the utero placental circulation. Decrease of the postdelivery growth rate has been reported as a secondary effect of daunorubicin to the exposed mice fetus. 6 This may explain our first case failure to thrive. Caliguri et al. 2 made a thorough review of the agents used to treat cancer. Table 1 summarizes the most commonly used agents and the way they act on dividing cells. Premature labor and low birth weight are the most common complications in patients with acute leukemia during pregnancy. 7 Most drugs used for the treatment of neoplasms are classified by the US Food and Drug Administration (FDA) as risk category D. That means there is evidence of human fetal risk, but the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks. 8 The first report of neonatal bone marrow hypoplasia as a complication of antileukemic therapy was published by Okun et al. 4 in 1979. Only one newborn was found to have pancytopenia among six studied by Pizzuto et al. 9 in 1980. The patient was a preterm and small-forgestation male who died of septicemia at 21 days of age. More recently, Morishita et al. 3 followed a patient with serial umbilical cord sampling, from 24 to 34 weeks' gestation, and concluded that fetal hematopoiesis may be preserved against maternal chemotherapy.
A 1991 review of 43 cases of infants born to mothers treated with chemotherapy during pregnancy was reported by Avilés et al. 1 They followed children from 3 to 19 years of age. This authors did physical examinations, and evaluated hematologic, renal, hepatic, neurologic, and psychologic status as well as intelligence and school performance. They found that eight children (43%) were pancytopenic at birth, which resolved between 3 and 10 weeks after delivery. No data are given about the treatment given. All other laboratory studies were normal. There were no abnormalities in their neurologic examinations. No congenital anomalies were observed, even in those treated during the first trimester. All children had normal intelligence. One of our patients presented severe pancytopenia. The mother was treated with daunorubicin and mitoxantrone 1 week before labor. Daunorubicin is known to produce myelosuppression, including pancytopenia, leukopenia, neutropenia, thrombocytopenia, and anemia. The nadir is within 10 to 14 days with recovery 7 days thereafter. The primary hematologic toxicity of liposomal daunorubicin is seen with the granulocytic cell series, whereas less severe effects are seen with platelets and the erythroid series. Mitoxantrone also produces myelosuppression. Neutropenia and thrombocytopenia are expected. Anemia and pancytopenia may also occur. The leukocyte count nadir usually occurs within 10 days and recovers in approximately 3 weeks. 10 Our patient's worst pancytopenia manifested at 6 days of life or approximately 2 weeks after her mother's chemotherapy when no neutrophils were seen on a blood smear. This makes us relate her hematologic derangement to transplacental passage of chemotherapeutic agents. Erythropoietin and G-CSF were given, starting at 6 days of life with recovery of anemia and neutropenia at the 13th day of life (see Figure 1) . She presented thrombocytopenia requiring platelet transfusions during the first week of life.
The current FDA indications for the use of G-CSF include the prevention and treatment of the chemotherapy-related febrile neutropenia, myeloid recovery after bone marrow transplantation, and treatment of severe chronic neutropenia (idiopathic, cyclic, or congenital). The safety and efficacy in neonates have not been established. 6 Our patient received G-CSF and showed a progressive increase in absolute neutrophil count with complete recovery after 7 days of therapy. No adverse effects attributable to the therapy were observed.
For granulocyte-macrophage colony stimulating factor (GM-CSF), indications are: the promotion of myeloid recovery after bone marrow transplantation, its recovery after standard dose chemotherapy, and the treatment of drug-induced bone marrow toxicity or neutropenia associated to AIDS. 10 During the last few years, Cairo et al. [11] [12] [13] have reported the use of G-CSF and GM-CSF in newborn rats. They have shown that recombinant murine GM-CSF administration to neonatal rats has resulted in neutrophilia, increased neutrophil production, and increased survival during experimental Staphylococcus aureus sepsis. More recently, Cairo 14 showed significant induction of circulatory neutrophils in very low birth weight neonates receiving recombinant human GM-CSF. They showed a significant increase in the circulating absolute neutrophil count as early as day 2 and a relative sustained neutrophilia for 120 hours after discontinuation. Also, there was a significant increase in the circulating platelet count after 7 days of treatment. They suggest that the use of GM-CSF in VLBW neonates may have a broad range of hematopoietic effects, including neutrophil maturation and production, monocyte production, and platelet production.
Recommendations for the use of recombinant human erythropoietin include: treatment of anemia in patients with chronic renal failure, zidovudine-induced anemia, anemia of prematurity, and anemia in cancer patients on chemotherapy. 10 The use of recombinant human erythropoietin in preterm infants has been studied in relation to the treatment or prevention of postnatal fall in hemoglobin, particularly in very low birth weights, reducing the need for transfusions. 15 Its effects can be seen after 2 weeks of treatment. This was seen in our first case who had a significant increase in reticulocyte count after 13 days of treatment. Reported adverse effects of erythropoietin such as diarrhea, nausea, edema, and seizures were not seen in our patient. She presented high blood pressure requiring treatment with hydralazine, which was transitory, and discontinuation of erythropoietin therapy was not needed.
There are other effects of chemotherapy important to our clinical practice. Cardiotoxicity can occur during chemotherapy with daunorubicin, including transient type abnormal electrocardiogram rhythms, as well as a cumulative, dose-dependent cardiomyopathy. Cardiotoxicity is more common in children than in adults. Mitoxantrone can cause functional cardiac changes, including decreases in left ventricular ejection fraction and congestive heart failure. Hepatotoxicity has also been reported with mitoxantrone. 10 Chemotherapy during pregnancy poses a risk to the fetus, which becomes less evident if it is administered after the onset of the third trimester. In respect to this, Zuazo et al. 16 made some recommendations when referring to hematologic malignancies: "(1) chemotherapy rarely interferes with pregnancy although it appears wise to postpone treatment until the end of the first trimester of pregnancy; (2) if therapy can not be delayed, it is better to avoid the folic acid antagonists or the prolonged use of alkylating agents; and (3) induction of labor or performance of a cesarean section whenever there is a viable fetus and the mother's blood counts are not compromised by recent treatment." With the advances of neonatal care, there is low morbidity for infants born beyond 34 completed weeks. 17 Despite a marked reduction in the mortality of preterm infants, approximately 50% to 60% of all neonatal deaths occur in the infants weighing Ͻ1000 gm at birth. 18 As in other cases where premature delivery is likely, the use of glucocorticoids for fetal lung maturation should be considered. Its use has been demonstrated to reduce the neonatal morbidity associated with respiratory distress, necrotizing enterocolitis, and intraventricular hemorrhages commonly seen in premature babies. 17 The National Institutes of Health have recommended the use of glucocorticoids in fetuses between 24 and 34 weeks' gestation. 19 It must be taken into account that some chemotherapeutic agents are associated with premature labor that will preclude elective delivery. Another important recommendation made by Zuazo is that breastfeeding is contraindicated because chemotherapeutic drugs may pass into milk.
Exposure of the fetus to transplacental chemotherapy must be considered when evaluating therapy options as well as timing of delivery in hematologic malignancies diagnosed during pregnancy. We have presented two infants born to mothers with hematologic malignancies who received chemotherapeutic treatment during pregnancy. One of them was started at 21 weeks' gestation and presented severe pancytopenia. The other was started at 28 weeks and presented moderate leukopenia without significant neutropenia. Early and repeated treatment with chemotherapy in the first patient had a profound effect in the bone marrow. However, both patients had a good outcome. If myelosuppression develops in the neonate, aggressive treatment is necessary to avoid complications such as bleeding, bacteremia, and septic shock. The therapy with colony stimulating factors and erythropoietin may be considered in view of the reported improvement in the clinical picture of our patient.
